Protein-based Covid vaccine applies for Swiss authorisation


ZURICH: American biotechnology company Novavax has applied for permission to supply its Covid-19 vaccine Nuvaxovid to Switzerland.

If approved by the medicines regulator Swissmedic, it would be the first protein-based vaccine to be made available in the country.

Because Novavax has no physical presence in Switzerland, it must apply for authorisation through the Swiss-based distributor Future Health.

Nuvaxovid has been approved for use in the EU by the European Medicines Agency (EMA). The Swiss application must be based on the same documents that were formerly submitted to the EMA.

Nuvaxovid contains the coronavirus spike protein, which trains the body to identify the virus and swiftly produce antibodies. The vaccine can be stored in conventional fridges for up to six months.

Swissmedic has to date approved mRNA vaccines from Pfizer/BioNTech and Moderna plus the viral vector alternative from Johnson & Johnson for use in Switzerland.


Send your News, Article, Pictorial

WhatsApp: +923132434567 / +923332100737 / +923002601786

Send your comments on enewspaper Social Media

Facebook: shujaullahk –
Twitter: KhanShujaullah –
LinkedIn: shuja-ullah-khan –